INVESCO Health Care Fund
Fund
GGHYX
Price as of:
$40.58
+ $0.41
+ 1.02%
Primary Theme
fund company
Name
As of 11/20/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
Vitals
YTD Return
7.9%
1 yr return
14.6%
3 Yr Avg Return
0.0%
5 Yr Avg Return
6.3%
Net Assets
$1.35 B
Holdings in Top 10
46.7%
52 WEEK LOW AND HIGH
$40.2
N/A
N/A
Expenses
OPERATING FEES
Expense Ratio 0.81%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover N/A
Redemption Fee N/A
Min Investment
Standard (Taxable)
$1,000
IRA
$250
Fund Classification
Fund Type
Open End Mutual Fund
Name
As of 11/20/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
GGHYX - Profile
Distributions
- YTD Total Return 7.9%
- 3 Yr Annualized Total Return 0.0%
- 5 Yr Annualized Total Return 6.3%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio 0.01%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annual
Fund Details
-
Legal NameINVESCO Health Care Fund
-
Fund Family NameINVESCOFDS
-
Inception DateOct 03, 2008
-
Shares OutstandingN/A
-
Share ClassY
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerJustin Livengood
Fund Description
The Fund invests, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of issuers engaged primarily in health care-related industries, and in derivatives and other instruments that have economic characteristics similar to such securities.
The Fund will concentrate its investments in the securities of domestic and foreign issuers in the health care industry. The Fund uses various criteria to determine whether an issuer is engaged in health care-related industries, including whether (1) it derives 50% or more of its gross income or its net sales from activities in the health care industry; (2) it devotes 50% or more of its assets to producing revenues from the health care industry; or (3) based on other available information, the Fund’s portfolio manager determines that its primary business is within the health care industry. Such other available information may include industry classifications from any one or more third-party providers, such as those using the Global Industry Classification Standard (GICS®), the North American Industry Classification System (NAICS), or the Bloomberg Industry Classification System (BICS).
Issuers engaged in health care-related industries include those that design, provide, distribute, manufacture, or sell products or services used for or in connection with health care or medicine (such as pharmaceutical issuers, biotechnology research firms, companies that make or sell medical products, and companies that own or operate health care facilities and systems).
The Fund invests primarily in equity securities, including common and preferred stock, and depositary receipts.
The Fund may invest in the securities of issuers of all capitalization sizes and may invest a significant amount of its net assets in the securities of small- and mid-capitalization issuers.
The Fund may invest in securities of foreign issuers including up to 20% of its net assets in securities of issuers located in emerging markets countries, i.e., those that are generally in the early stages of their industrial cycles.
The Fund can invest in derivative instruments, including forward foreign currency contracts. The Fund can use forward foreign currency contracts to hedge against adverse movements in the foreign currencies in which portfolio securities are denominated.
In selecting securities for the Fund, the portfolio manager uses a research-oriented bottom-up investment approach,focusing on issuer fundamentals before considering the impact of overall economic,market or industry trends.This approach includes analysis of a company's financial statements and management structure andconsideration of the company's operations,product development, and itsindustry position.The portfolio manager currently focuses on companies that the portfolio manager believes are characterized by industry leadership, market share growth, high
caliber management teams, sustainable competitive advantages, and strong growth themes or new innovative products or services.The portfolio manager monitors individual issuers for changes in the factors above, which may trigger a decision to sell a security,but does not require a decision to do so. The factors considered by the portfolio manager may vary in particular cases and may change over time.
GGHYX - Performance
Return Ranking - Trailing
| Period | GGHYX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 7.9% | -29.1% | 19.1% | 32.08% |
| 1 Yr | 14.6% | -17.5% | 44.4% | 49.69% |
| 3 Yr | 0.0%* | -30.1% | 8.6% | 51.32% |
| 5 Yr | 6.3%* | -7.8% | 11.8% | 67.12% |
| 10 Yr | 4.4%* | 0.0% | 13.1% | 81.08% |
* Annualized
Return Ranking - Calendar
| Period | GGHYX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | 4.2% | -12.6% | 19.0% | 28.30% |
| 2022 | -13.3% | -53.9% | 3.2% | 60.53% |
| 2021 | -9.9% | -39.6% | 24.2% | 73.03% |
| 2020 | 7.5% | -13.6% | 178.2% | 73.15% |
| 2019 | 27.5% | 3.8% | 63.8% | 12.78% |
Total Return Ranking - Trailing
| Period | GGHYX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | 7.9% | -29.1% | 19.1% | 32.08% |
| 1 Yr | 14.6% | -17.5% | 44.4% | 49.69% |
| 3 Yr | 0.0%* | -30.1% | 8.6% | 51.32% |
| 5 Yr | 6.3%* | -7.8% | 11.8% | 67.12% |
| 10 Yr | 4.4%* | 0.0% | 13.1% | 81.08% |
* Annualized
Total Return Ranking - Calendar
| Period | GGHYX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | 4.2% | -12.6% | 19.0% | 46.54% |
| 2022 | -13.3% | -53.9% | 3.7% | 73.68% |
| 2021 | 12.5% | -33.9% | 26.0% | 31.58% |
| 2020 | 14.7% | -0.7% | 180.6% | 75.17% |
| 2019 | 32.2% | 4.6% | 63.8% | 22.56% |
NAV & Total Return History
GGHYX - Holdings
Concentration Analysis
| GGHYX | Category Low | Category High | GGHYX % Rank | |
|---|---|---|---|---|
| Net Assets | 1.35 B | 6.66 M | 45.7 B | 35.85% |
| Number of Holdings | 80 | 25 | 430 | 49.69% |
| Net Assets in Top 10 | 643 M | 2.12 M | 22.1 B | 33.33% |
| Weighting of Top 10 | 46.65% | 18.4% | 79.7% | 50.31% |
Top 10 Holdings
- Eli Lilly and Co. 8.50%
- Boston Scientific Corp. 5.80%
- UnitedHealth Group Inc. 5.23%
- McKesson Corp. 4.28%
- Danaher Corp. 4.24%
- Vertex Pharmaceuticals Inc. 3.89%
- Intuitive Surgical, Inc. 3.82%
- Merck Co., Inc. 3.72%
- AstraZeneca PLC, ADR 3.63%
- Regeneron Pharmaceuticals, Inc. 3.56%
Asset Allocation
| Weighting | Return Low | Return High | GGHYX % Rank | |
|---|---|---|---|---|
| Stocks | 96.52% | 87.34% | 106.13% | 79.25% |
| Cash | 7.61% | 0.00% | 33.01% | 11.32% |
| Preferred Stocks | 0.00% | 0.00% | 7.86% | 48.43% |
| Other | 0.00% | -22.99% | 23.24% | 47.80% |
| Convertible Bonds | 0.00% | 0.00% | 0.37% | 25.97% |
| Bonds | 0.00% | 0.00% | 12.39% | 45.91% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | GGHYX % Rank | |
|---|---|---|---|---|
| Healthcare | 100.00% | 59.26% | 100.00% | 11.69% |
| Utilities | 0.00% | 0.00% | 0.00% | 19.48% |
| Technology | 0.00% | 0.00% | 22.69% | 24.03% |
| Real Estate | 0.00% | 0.00% | 5.89% | 23.38% |
| Industrials | 0.00% | 0.00% | 7.02% | 23.38% |
| Financial Services | 0.00% | 0.00% | 1.60% | 40.91% |
| Energy | 0.00% | 0.00% | 0.00% | 19.48% |
| Communication Services | 0.00% | 0.00% | 9.11% | 22.73% |
| Consumer Defense | 0.00% | 0.00% | 25.73% | 28.57% |
| Consumer Cyclical | 0.00% | 0.00% | 1.92% | 23.38% |
| Basic Materials | 0.00% | 0.00% | 7.16% | 48.05% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | GGHYX % Rank | |
|---|---|---|---|---|
| US | 91.08% | 66.06% | 104.41% | 56.60% |
| Non US | 5.43% | 0.00% | 28.87% | 38.99% |
GGHYX - Expenses
Operational Fees
| GGHYX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 0.81% | 0.08% | 4.48% | 64.78% |
| Management Fee | 0.63% | 0.03% | 1.25% | 35.85% |
| 12b-1 Fee | N/A | 0.00% | 1.00% | N/A |
| Administrative Fee | N/A | 0.03% | 0.25% | N/A |
Sales Fees
| GGHYX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 3.50% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 1.00% | N/A |
Trading Fees
| GGHYX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 1.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| GGHYX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | N/A | 0.00% | 238.00% | 9.43% |
GGHYX - Distributions
Dividend Yield Analysis
| GGHYX | Category Low | Category High | GGHYX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 6.24% | 45.91% |
Dividend Distribution Analysis
| GGHYX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annual | Annual | Annual | Annual |
Net Income Ratio Analysis
| GGHYX | Category Low | Category High | GGHYX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | 0.01% | -2.54% | 1.85% | 32.24% |
Capital Gain Distribution Analysis
| GGHYX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Annually | Annually |
Distributions History
| Date | Amount | Type |
|---|---|---|
| Dec 16, 2021 | $9.930 | CapitalGainLongTerm |
| Dec 15, 2020 | $3.004 | OrdinaryDividend |
| Dec 13, 2019 | $0.198 | OrdinaryDividend |
| Dec 13, 2019 | $1.370 | CapitalGainLongTerm |
| Dec 14, 2018 | $0.113 | CapitalGainShortTerm |
| Dec 14, 2018 | $2.790 | CapitalGainLongTerm |
| Dec 13, 2017 | $2.448 | CapitalGainLongTerm |
| Dec 13, 2016 | $0.737 | CapitalGainLongTerm |
| Dec 13, 2016 | $0.172 | OrdinaryDividend |
| Dec 12, 2014 | $0.007 | CapitalGainShortTerm |
| Dec 12, 2014 | $4.924 | CapitalGainLongTerm |
| Dec 12, 2014 | $0.015 | OrdinaryDividend |
| Dec 13, 2013 | $0.235 | CapitalGainShortTerm |
| Dec 13, 2013 | $3.220 | CapitalGainLongTerm |
| Dec 13, 2013 | $0.103 | OrdinaryDividend |
| Sep 19, 2013 | $0.051 | OrdinaryDividend |
| Dec 07, 2012 | $2.241 | CapitalGainLongTerm |
| Dec 07, 2012 | $0.202 | OrdinaryDividend |
| Dec 09, 2011 | $0.483 | CapitalGainLongTerm |
| Dec 09, 2011 | $0.213 | OrdinaryDividend |
| Dec 12, 2008 | $0.601 | CapitalGainLongTerm |
GGHYX - Fund Manager Analysis
Managers
Justin Livengood
Start Date
Tenure
Tenure Rank
Dec 18, 2020
1.45
1.5%
Mr. Livengood has been a Vice President of OppenheimerFunds since May 2006 and a Senior Portfolio Manager since January 2014. He was a Senior Research Analyst from May 2006 to January 2014, responsible for the health care, energy and financial services sectors for mid- and small-cap growth accounts. Before joining OppenheimerFunds in May 2006, Mr. Livengood was a vice president and fund analyst with Merrill Lynch Investment Managers. During his tenure at Merrill Lynch he also worked as an investment banking analyst in the Global Media Group and as an associate with Merrill Lynch Ventures.
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.02 | 24.72 | 7.88 | 0.25 |